“The UN is the lead global institution dealing with many of these challenges,” he told the Global Colloquium of University Presidents on New Technologies for Meeting Global Challenges at Yale University in the United States yesterday, citing this week’s devastating earthquake in Haiti as a prime example of the need to close the technology gap between developing and developed countries. “We have technologies to build sturdier buildings and to build infrastructures that take into account possible fault lines. We know a great deal about how to work with the natural landscape to ensure that urban settlements are more secure. The problem is that so many parts of the world are not benefiting from this knowledge and these technologies. Disaster risk reduction measures must not be a luxury that only some States can afford.”But the gap between the haves and the have-nots is not the only challenge in harnessing technology to drive development. No technology is risk-free and its responsible use is therefore crucial, Mr. Ban stressed.“Technological development has opened the door to a host of new global threats. Some of these are quite horrifying. A dangerous virus could escape the confines of a high-security lab; or terrorists could steal nuclear materials from medical or energy facilities and turn them into weapons. A synthetically produced organism could have an adverse impact on the environment or on health,” he said. “It is clear that we must create an environment in which science and technological innovation can flourish, but with robust safeguards and oversight mechanisms, which protect both people and the environment from unacceptable risks,” he added.He highlighted wide-ranging UN experience on the issue, citing the Nuclear Non-Proliferation Treaty which the UN International Atomic Energy Agency (IAEA) helps monitor, but warned that biotechnology and cyberspace are two areas of research where efforts to control the risks nationally and internationally are not keeping pace with innovation. 15 January 2010The United Nations has a vital role to play in helping Member States, particularly those in the developing world, to harness new technologies to mitigate natural disasters, climate change, food shortages and a host of other challenges, according to Secretary-General Ban Ki-moon.
AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to RedditRedditShare to 電子郵件Email Pfizer 2Q adj. profit beats, revenue misses Wall Street’s view; reiterates 2013 outlook by Linda A. Johnson, The Associated Press Posted Jul 30, 2013 6:37 am MDT Pfizer’s second-quarter net income more than quadrupled, helped by the sale of its animal health business and a gain from settling litigation.The world’s second-largest drugmaker beat Wall Street’s earnings expectations, though revenue continued to decline due to expired patents on former blockbuster drugs that once brought Pfizer sales of well over $1 billion a year.Meanwhile, just a day after Pfizer announced it will reorganize into three businesses starting in January, analysts peppered company executives on a conference call with questions about how soon it could split up into multiple companies. Pfizer said that would take at least three years, but it hasn’t decided to do so.The company noted unfavourable exchange rates cut revenue by 3 per cent. Worse yet, Pfizer said growth is slowing in emerging markets such as China and India.The company now expects that revenue to climb in 2013 by only a mid-single-digit percentage, down from prior forecasts of high-single-digits. That’s worrying because the pharmaceutical industry has pinned most hopes for future growth on those countries, as western governments continue to try to rein in prices.“The emerging markets did not grow as fast as we expected,” Pfizer CEO Ian Read told The Associated Press in an interview. “This is in part due to some slowing up of purchases and some pricing pressure” by governments in emerging markets.Still, the biggest problem was a continuing revenue decline due generic competition. The worst hit has been on cholesterol fighter Lipitor, which was the world’s bestselling drug for nearly a decade until it lost exclusivity in the U.S. late in 2011 and in much of Europe last year. Revenue from Lipitor, which once brought in nearly $13 billion a year, dropped 55 per cent to $484 million in the second quarter. Meanwhile, generic rivals also hurt sales of Alzheimer’s symptom treatment Aricept and Spiriva, an inhaler for respiratory conditions.When drug patents expire, generic versions flood the market and their prices eventually drop up to 90 per cent. Most patients quickly switch to them.Read told the AP that from now through 2016, Pfizer each year faces patent expirations for drugs with annual sales totalling $3.5 billion to $4 billion.Many analysts have “Buy” recommendations for Pfizer, though, because of promising new and experimental drugs.Pfizer, which makes Viagra and the pain medicines Lyrica and Celebrex, earned $14.1 billion, or $1.98 per share. That compares with $3.25 billion, or 43 cents per share, a year earlier.Pfizer, long under pressure to boost what shareholders get from its dividends and share price appreciation, has been working to sell off non-core businesses and focus on prescription medicines, particularly for disorders lacking good treatments.The company’s second-quarter profit jumped mainly on the spin-off of its animal drug business, completed in late June when it divested its remaining 80 per cent stake in the new company, called Zoetis Inc. That gave Pfizer an after-tax gain of $10.6 billion, bringing its total take from the spinoff to $17.2 billion.New York-based Pfizer also received $1.4 billion from a patent settlement with two companies that sold generic versions of popular heartburn treatment Protonix while they were challenging its patent, which hadn’t yet expired.Excluding those gains, earnings were 56 cents per share, a penny better than expected.The company said overall revenue fell 7 per cent to $12.97 billion, just short of the $13.21 billion analysts polled by FactSet had predicted.In midday trading, shares were up 23 cents at $29.77.Pfizer has already divested its nutrition and capsule-making businesses and on Monday announced a reorganization into three divisions.One will be devoted to products that have lost patent protection, or will through 2015. Those include Viagra, Celebrex, Lyrica and antibiotic Zyvox — but only in some countries. Another division will handle drugs with years of patent protection remaining. The third that will sell vaccines, cancer medicines and consumer products such as Centrum vitamins.Leerink Swan analyst Seamus Fernandez said the restructuring “offers greater flexibility to continue the current shareholder friendly strategy of further focusing the business on its core operating businesses.”Pfizer also announced plans to repurchase $10 billion in company shares, on top of $3.1 billion remaining under its previous buyback program.Revenue from Prevnar 13, a vaccine for ear infections, meningitis and other pneumococcal infections, fell 3 per cent to $969 million. Prevnar is the biggest-selling vaccine in history, with nearly $4 billion in yearly revenue.Sales of Lyrica, for fibromyalgia and other pain, grew 10 per cent to $1.13 billion, and anti-inflammatory pain reliever Celebrex rose 8 per cent to $715 million.Sales of impotence drug Viagra were nearly flat at $484 million despite a precedent-setting move in May to start selling it online to counteract massive counterfeiting on the Internet.___Linda A. Johnson can be followed at http://twitter.com/LindaJ_onPharma___AP Business Writers Matt Perrone in Washington and Michelle Chapman in New York contributed to this report.
Some imagined what the letter might say… The official photo of @NicolaSturgeon signing the section 30 request for an independence referendum is absolute patter. 💯👏💯 pic.twitter.com/l1rQhNVNvH— The Cherry Wave (@TheCherryWave) March 30, 2017 Just got sent the section 30 letter pic.twitter.com/xsxD4aML3n— Liam O’Hare (@Liam_O_Hare) March 30, 2017 Theresa May puts the final touches art 50 letter @NicolaSturgeon puts final touches to section 30 letter. #ScotRef #ScotlandinEurope pic.twitter.com/yJLTD1Sz20— Susanne Campbell SNP (@susannecc) March 30, 2017 Well, you know what they say about imitation and flattery…. pic.twitter.com/R7SltrrWjW— Ruth Davidson (@RuthDavidsonMSP) March 30, 2017 Nicola Sturgeon’s pose as she signed her letter asking for a second independence referendum couldn’t have been more different from Theresa May’s as she signed the Article 50 letter.Curled on the sofa like a satisfied cat, with her feet up and a beverage resting on the table next to her, she smiled as she signed the letter which could cause a huge headache for the UK Government. Want the best of The Telegraph direct to your email and WhatsApp? Sign up to our free twice-daily Front Page newsletter and new audio briefings. Many on social media have imagined what the contents of the letter say, and wondered if she purposefully posed so casually to irritate the Prime Minister.Pleased Scots referred to the letter and pose as “absolute patter”, while others derided her casual approach. “Dear Slim, I wrote but you still ain’t called.” #indyref2 #scotref pic.twitter.com/5uLk3Axx8N— Scott Reid (@scottreid1980) March 30, 2017 Theresa May puts the final touches art 50 letter @NicolaSturgeon puts final touches to section 30 letter. #ScotRef #ScotlandinEurope pic.twitter.com/yJLTD1Sz20— Susanne Campbell SNP (@susannecc) March 30, 2017 Theresa May’s reply to Nicola Sturgeon’s Section 30 letter is pretty blunt pic.twitter.com/cjziFRb2Zv— Charlie (@chralie) March 30, 2017 Here’s the FM writing the section 30 letter to the PM – a more casual look than the A50 letter & no flag. #indyref2 pic.twitter.com/PTmpCrtUFG— Mark Diffley (@markdiffley1) March 30, 2017 And Ruth Davidson made a comparison Nicola Sturgeon may not enjoy And what Mrs May’s response may be